SL Science Submits Orphan Drug Designation Request To FDA For Gamma Delta T Cell Therapy Product, Vdelta2+ Gamma Delta T Cells, For Treatment Of Glioblastoma Multiforme

Loading news article.

SL Science Submits Orphan Drug Designation Request To FDA For Gamma Delta T Cell Therapy Product, Vdelta2+ Gamma Delta T Cells, For Treatment Of Glioblastoma Multiforme | WAPE

SL Science Submits Orphan Drug Designation Request To FDA For Gamma Delta T Cell Therapy Product, Vdelta2+ Gamma Delta T Cells, For Treatment Of Glioblastoma Multiforme

Article summary

Related companies

Comments —